• Home
  • Research
  • Research News
  • Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin

Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin

Neuroendocrinology, 07/05/2013


Jann H et al. – The aim of the investigation was to evaluate the antiproliferative effect of Somatostatin analogues (SSA) in patients with pancreatic neuroendocrine tumours (NET). SSA may be considered as first–line treatment for antiproliferative purposes in metastatic NET of the pancreas. Patients with a proliferation index of less than 10% displayed a more durable response compared to those with a higher proliferation index.

Print

Available Now!

PPRG6-500 Cover
The Pituitary Patient Resource Guide Sixth Edition is now available! Be one of the first to have the most up-to-date information. The Pituitary Patient Resource Guide a one of a kind publication intended as an invaluable source of information not only for patients but also their families, physicians, and all health care providers. It contains information on symptoms, proper testing, how to get a diagnosis, and the treatment options that are available. It also includes Pituitary Network Association's patient resource listings for expert medical care.

Buy Now